Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Cecilia Lindgren has been appointed as the new Director of the University of Oxford’s Big Data Institute.

Big Data Institute building and Professor Cecilia Lindgren

The availability of biomedical information, also known as ‘big data’, is increasing rapidly. The analysis of this data provides an opportunity for transforming the scale and efficiency of large-scale clinical research and care.

The Big Data Institute (BDI) brings together researchers from different disciplines to focus on the analysis of large, complex, heterogeneous data sets for research into the causes, consequences, prevention and treatment of disease. Their work is invaluable in identifying the associations between lifestyle, genetic variants, infections, and health outcomes for people around the world.

Professor Cecilia Lindgren's work focuses on understanding the mechanisms involved in common complex traits, particularly obesity, by applying a range of genetic and genomic approaches to identify genetic risk variants and dissect their function. This knowledge will support therapeutic advances through development of new diagnostic tools and possible drug targets.

Read the full story on the Big Data Institute website.

Similar stories

Tamoxifen repurposing study shows no benefit in treating deadly fungal meningitis

Hopes that tamoxifen could improve survival for a deadly form of fungal meningitis have been dashed by the results of a clinical trial conducted by University of Oxford researchers and published today in eLife.

Oxford researchers awarded funding to complete community COVID-19 antiviral trial

Researchers from the Nuffield Department of Primary Care Health Sciences, University of Oxford, have today announced that they have been awarded funding through the National Institute for Health Research (NIHR) to work with several UK universities and carry out a first-of-its-kind clinical trial, testing novel antiviral COVID-19 treatments for use early on in the illness by people in the community with COVID-19 who are at higher risk of complications.

New therapeutic targets identified to treat inflammatory bowel disease

Millions of patients with ulcerative colitis or Crohn’s disease, collectively known as inflammatory bowel disease (IBD), are given fresh hope as a new study shows why some of them do not respond to current treatments.

Oxford researchers call for an urgent re-evaluation of “weak” opioid safety profile

A new study associates dispensation doses of tramadol with increased risk of mortality, cardiovascular events, and fractures compared to the use of codeine to treat pain.

Labelling proteins through the diet gives new insights into how collagen-rich tissues change as we age

A new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.

Drug could help diabetic hearts recover after heart attack - Oxford research

Researchers at the University of Oxford have identified a drug that could ultimately help improve heart function in people with diabetes who have heart attacks.